The concern of generic competition has long loomed over copyright’s iconic drug, Sildenafil, triggering questions about the outlook of connected pharmaceutical investments. While early times saw substantial gains, the exclusivity expiration has opened the door for cheaper substitutes, possibly reducing revenue and presenting a genuine danger for